Uptake of Workplace HIV Counselling and Testing: A Cluster-Randomised Trial in Zimbabwe by Corbett, Elizabeth L et al.
Uptake of Workplace HIV Counselling
and Testing: A Cluster-Randomised Trial
in Zimbabwe
Elizabeth L. Corbett
1,2*, Ethel Dauya
2, Ronnie Matambo
2, Yin Bun Cheung
1, Beauty Makamure
2, Mary T. Bassett
3,
Steven Chandiwana
2,4, Shungu Munyati
5, Peter R. Mason
2,6, Anthony E. Butterworth
1,2, Peter Godfrey-Faussett
1,
Richard J. Hayes
1
1 Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom, 2 Biomedical Research and Training Institute,
Harare, Zimbabwe, 3 Department of Community Medicine, University of Zimbabwe, Harare, Zimbabwe, 4 Faculty of Health Sciences, University of the Witwatersrand,
Witwatersrand, South Africa, 5 National Institute of Health Research, Harare, Zimbabwe, 6 Department of Medical and Laboratory Sciences, University of Zimbabwe, Harare,
Zimbabwe
Funding: The study was funded by
the Wellcome Trust, through a
Career Development Award to ELC.
The funders had no role in study
design, data collection and analysis,
decision to publish, or preparation
of the manuscript.
Competing Interests: The authors
have declared that no competing
interests exist.
Academic Editor: Joshua A.
Salomon, Harvard School of Public
Health, United States of America
Citation: Corbett EL, Dauya E,
Matambo R, Cheung YB, Makamure
B, et al. (2006) Uptake of workplace
HIV counselling and testing: A
cluster-randomised trial in
Zimbabwe. PLoS Med 3(7): e238.
DOI: 10.1371/journal.pmed.0030238
Received: January 3, 2006
Accepted: April 4, 2006
Published: July 4, 2006
DOI:
10.1371/journal.pmed.0030238
Copyright:  2006 Corbett et al.
This is an open-access article
distributed under the terms of the
Creative Commons Attribution
License, which permits unrestricted
use, distribution, and reproduction
in any medium, provided the
original author and source are
credited.
Abbreviations: CI, confidence
interval; OR, odds ratio; TB,
tuberculosis; VCT, voluntary
counselling and testing
* To whom correspondence should
be addressed. E-mail: elc1@mweb.
co.zw
ABSTRACT
Background
HIV counselling and testing is a key component of both HIV care and HIV prevention, but
uptake is currently low. We investigated the impact of rapid HIV testing at the workplace on
uptake of voluntary counselling and testing (VCT).
Methods and Findings
The study was a cluster-randomised trial of two VCT strategies, with business occupational
health clinics as the unit of randomisation. VCT was directly offered to all employees, followed
by 2 y of open access to VCT and basic HIV care. Businesses were randomised to either on-site
rapid HIV testing at their occupational clinic (11 businesses) or to vouchers for off-site VCT at a
chain of free-standing centres also using rapid tests (11 businesses). Baseline anonymised HIV
serology was requested from all employees.
HIV prevalence was 19.8% and 18.4%, respectively, at businesses randomised to on-site and
off-site VCT. In total, 1,957 of 3,950 employees at clinics randomised to on-site testing had VCT
(mean uptake by site 51.1%) compared to 586 of 3,532 employees taking vouchers at clinics
randomised to off-site testing (mean uptake by site 19.2%). The risk ratio for on-site VCT
compared to voucher uptake was 2.8 (95% confidence interval 1.8 to 3.8) after adjustment for
potential confounders. Only 125 employees (mean uptake by site 4.3%) reported using their
voucher, so that the true adjusted risk ratio for on-site compared to off-site VCT may have been
as high as 12.5 (95% confidence interval 8.2 to 16.8).
Conclusions
High-impact VCT strategies are urgently needed to maximise HIV prevention and access to
care in Africa. VCT at the workplace offers the potential for high uptake when offered on-site
and linked to basic HIV care. Convenience and accessibility appear to have critical roles in the
acceptability of community-based VCT.
The Editors’ Summary of this article follows the references.
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Rapid scale-up of HIV care programs is ongoing in Africa,
driven by ambitious targets set by the World Health
Organization in 2003 and accompanied by the simultaneous
need to intensify HIV prevention [1,2]. HIV counselling and
testing is a key component of both care and prevention, but
has so far reached only a minority of Africans. A median of
9% of men and 7% of women reported ever having had an
HIV test in surveys conducted in 25 African countries since
2000 [3].
Three previous randomised trials have compared uptake
under different HIV testing strategies. These have established
that rapid HIV testing with same day results reduced non-
receipt of results, but had little effect on uptake when the
indications for testing were pregnancy and sexually trans-
mitted infections [4,5]. For voluntary counselling and testing
(VCT) in the community, however, uptake was signiﬁcantly
increased in Zambia by home-based delivery of results and
counselling [6]. Observational studies have concurred that
convenience, direct offer of testing, and positive attitude of
staff have a critical impact on uptake of HIV testing, and
appear to outweigh individual client-related factors [7–13].
Workplace-based initiatives have the potential to expand
access to HIV care in Africa at minimal cost to government
[14]. We compared two VCT strategies linked to basic HIV
care delivered through occupational clinics in small- and
medium-sized businesses in Harare, Zimbabwe. A cluster-
randomised design was used because the intervention was at
the clinic level and the primary outcome concerned the
potential beneﬁt of providing VCT and HIV care at the
workforce level. Zimbabwe has an estimated adult HIV
prevalence of 25% [15]. Participating businesses were
randomised either to counselling plus on-site rapid HIV
testing or to counselling plus vouchers for off-site HIV testing
at a chain of free-standing VCT centres. Both strategies were
linked to the same package of basic HIV care. The aims were
to compare the uptake of HIV testing and subsequent
incidence of HIV-related morbidity and mortality under
these two VCT/HIV care strategies. Here we report uptake.
Methods
Study Sites and Participants
Businesses operating within Harare were identiﬁed with
the assistance of an HIV prevention project working with
businesses (Zimbabwe AIDS Prevention Project), and were
eligible if they had (i) 100 to 600 employees, (ii) an
occupational or ﬁrst aid clinic, and (iii) individual-based
absenteeism records. Payrolls, used to identify all employees,
were re-examined every three months for new employees and
loss to employment. All employees expected to remain
employed for at least 3 mo were eligible to participate.
Randomisation
Businesses were categorised into high, medium, or low
absenteeism strata using 3 mo of summary records. Alloca-
tion to the two VCT strategies used stratiﬁed randomisation
within these three absenteeism strata (computer program
written and run by ELC in STATA 6.0; Stada, College Station,
Texas, United States). Sample size was based on the potential
impact of the intervention on health outcomes (to be
reported separately). Randomisation occurred between en-
rolment and baseline interviews.
Intervention
All eligible employees, including new employees during
follow-up, were invited for interview when VCT was offered
with pre-test counselling, individual risk assessment, and risk
reduction plans. Participants at sites randomised to on-site
rapid testing then had testing, results, and post-test counsel-
ling on the same day. Employees at sites randomised to the
off-site strategy were given vouchers for off-site VCT and a 2-
wk appointment to discuss results. The off-site VCT providers
(New Start) had multiple branches in and around Harare
situated at convenient locations (bus terminals and major
shopping centres) that offered services after normal working
hours and at weekends. After three reminders employees who
had taken vouchers but reported not having used them were
considered to have taken a voucher but not had VCT. This
trial is reported in accordance with CONSORT guidelines
(Protocol S1). The study protocol, including the patient
consent forms can be found in Protocol S2.
Counselling sessions were periodically observed by a
supervisor who also conducted exit interviews. Debrieﬁng
meetings and refresher training were held every 2 wk and 6
mo, respectively.
HIV-positive employees were offered a package of care
delivered through their occupational clinic, including post-
test counselling, health education, vouchers for HIV testing of
partners, and isoniazid preventive therapy and/or cotrimox-
azole prophylaxis when indicated (tuberculin skin test
positive with no evidence of active tuberculosis [TB] disease,
and World Health Organization HIV clinical stages 2 to 4,
respectively). The beneﬁts of antiretroviral therapy, which
was not part of this intervention, were discussed, and referral
was made to local providers who became available during the
second year of the study. Study nurses visited each clinic
according to a schedule (at least three times a week) to
provide ongoing HIV care, and open access to primary health
care and the allocated VCT strategy for 2 y, after which
service provision was continued by Zimbabwe AIDS Preven-
tion and Support Organization. The start of intervention was
staggered over 10 mo across the 22 businesses. Follow-up was
for 2 y at each site and was completed for the last businesses
in July 2004.
Demography and Anonymised HIV Tests
All employees, whether accepting VCT or not, were asked
to complete a questionnaire and provide venous or ﬁnger-
prick blood or oral mucosal transudate for anonymised HIV
testing, with written informed consent, at both the start and
the ﬁnish of the intervention. Results of anonymised HIV
tests were not made available to participants or clinic staff.
Laboratory Methods
Anonymised HIV testing used Determine (Abbott, Wiesba-
den, Germany) for blood and Vironostika II plus O
(bioMerieux, Durham, North Carolina, United States) for
oral mucosal transudate. One in ten specimens were retested
for quality assurance (Unigold [Trinity Biotech, Dunblane,
United Kingdom] for serum specimens, Vironostika II plus O
for dried blood spots, and OraQuick [OraSure Technologies,
Bethlehem, Pennsylvania, United States] for oral mucosal
transudate).
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Cluster-Randomised Trial of VCT UptakeOn-site VCT was carried out by trained nurse-counsellors,
using parallel Determine and Unigold with either venous or
ﬁnger-prick blood. A written policy for discordant results and
a quality assurance program were in place.
Ethical Considerations
Anonymised HIV specimens were run, stored, and held
apart from all personal identiﬁers other than a laboratory
number. These were merged to other data using a linking ﬁle
and computer program that immediately deleted all personal
identiﬁers to maintain complete conﬁdentiality during
analysis.
Written informed consent was obtained from all partic-
ipants. The study was approved by the ethics committees of
the London School of Hygiene and Tropical Medicine and
the Medical Research Council of Zimbabwe, Harare.
Data Analysis
Comparison of the characteristics of participants used
robust standard errors that took clustering at workplace level
into account [16]. VCT uptake was analysed as a binary
variable, because acceptance was not dependent on length of
follow-up time, with most employees accepting shortly after
direct offer: new employees were as likely to participate as
those present for the entire study period. Only ﬁrst episodes
of VCT or voucher uptake were considered in the main
analysis. Individuals moving between study businesses were
considered under their ﬁrst position only, so that any given
individual could only account for one record. Associations
between VCT uptake under each strategy and demographic
and health variables were assessed by logistic regression, with
robust standard errors. Based on cluster-randomised trial
methodology, the data were reduced to 22 records [17,18].
Wilcoxon rank sum tests were used to compare the
proportions of participants who received VCT between the
two arms of the trial. Risk ratios and 95% conﬁdence
intervals (CIs) are also reported.
Multivariate analysis was used to adjust for the stratiﬁed
randomisation and other potential confounders, using
logistic regression to predict the expected number of VCT
users and the ratio of observed and expected numbers of
events (standardised incidence ratio) as the outcome measure
[17].
Results
A total of 29 businesses were assessed, of which 26 were
eligible. Two withdrew before randomisation, and two were
withdrawn between randomisation and intervention (Figure
1). The cumulative number of employees during the 2-y
intervention was 7,482 for the 22 participating businesses,
including 1,305 employees who joined after the start of the
intervention. Businesses were in manufacturing of hardware,
construction, or industrial goods (14); clothing (3); food (3);
and telecommunications (2). Participation rates were 91.3%
for baseline interview and 86.0% for anonymised HIV testing.
Baseline characteristics did not differ signiﬁcantly by
allocated VCT strategy, and are shown in Table 1.
Uptake of On-Site HIV Testing Compared to Voucher
Uptake
Uptake of VCT with on-site rapid testing was signiﬁcantly
and substantially greater than voucher uptake (Figure 2;
Table 2). A total of 1,957 employees at businesses allocated
Figure 1. Trial Summary
DOI: 10.1371/journal.pmed.0030238.g001
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Cluster-Randomised Trial of VCT Uptakeon-site rapid testing accepted VCT at least once (mean
uptake by site 51.1%). There were no serious adverse events
resulting from VCT. Under the off-site voucher strategy, 586
employees accepted vouchers at least once (mean uptake per
site 19.2%). The difference was signiﬁcant, with a risk ratio of
2.7 (95% CI 1.8 to 3.9) after adjustment for the cluster-
randomised design (Table 2). The risk ratio was 2.8 (95% CI
1.8 to 3.8) on further adjustment for differences in age, sex,
marital status, education, self-rated health, and absenteeism
strata.
Previous VCT episodes were reported by 73 (12.5%) of the
586 employees who took vouchers and by 293 (15.0%) of
employees accepting VCT at the workplace. A similar
percentage of HIV-positive and HIV-negative clients re-
ported previous VCT, suggesting that prior knowledge of HIV
infection did not have a major impact on participation under
either randomisation arm.
Uptake of On-Site VCT Compared to Reported Off-Site
VCT Attendance
Having accepted vouchers, only 125 employees reported
having attended off-site VCT by their third reminder (21.3%
of those taking vouchers; mean uptake per site 4.3%).
Assuming that late or concealed attendance was negligible,
the adjusted risk ratio for accepting on-site VCT compared to
attending off-site VCT was 12.5 (95% CI 8.2 to 16.8), as shown
in Table 2 and Figure 2.
Time Course of First VCT Uptake
VCT was available for 2-y at each site, but direct offer was
made to each employee only once, unless HIV testing was
indicated because of an HIV-related illness. The timing of
ﬁrst uptake among participants who accepted at least one on-
site VCT or voucher is shown in Figure 3. Among employees
who were present at the start of intervention, 1,239 (75.5%) of
1,640 who accepted VCT with rapid HIV testing did so within
the ﬁrst 2 mo of the intervention, with the corresponding
proportion for voucher uptake being 274 (62.7%) of 437
participants. The high early uptake in part reﬂects the impact
of direct offer, but there was obvious collective enthusiasm
for on-site HIV testing, with demand outstripping counselling
capacity in the ﬁrst few weeks. Another possible manifes-
tation of group dynamics, whereby employees encouraged
Table 1. Baseline Characteristics according to Randomisation
Group
Variable Type Characteristic VCT through
Off-Site
Voucher
VCT through
On-Site Rapid
Testing
Cluster level Number of businesses 11 11
Months VCT available (SD) 23.6 (0.4) 23.7 (0.3)
Number of employees
a 3,532 3,950
Absenteeism strata (%)
—High 220 (6.2) 352 (8.9)
—Medium 1,801 (51.0) 2,301 (58.3)
—Low 1,511 (42.8) 1,297 (32.8)
Months VCT available (SD) 23.6 (0.4) 23.7 (0.3)
Individual level Mean age (SD)
a,b 35.9 (10.8) 35.3 (10.9)
Male gender
a,c (%) 2,933 (86.9) 3,414 (88.8)
Marital status
a,d (%)
—Single 653 (20.2) 729 (20.3)
—Married/cohabiting 2,383 (73.8) 2,656 (73.8)
—Previously married
e 195 (6.0) 214 (5.9)
Education
a,d (%)
—None/primary 597 (18.5) 673 (18.7)
—Secondary 2,243 (69.4) 2,555 (71.0)
—Higher 391 (12.1) 371 (10.3)
Religion
a,d (%)
—Christian 2,558 (79.2) 2,842 (79.0)
—None/other 673 (20.8) 757 (21.0)
Household contact with
TB in past
a,f (%)
578 (17.2) 581 (15.3)
Known HIV status
g (%) 3,045 (86.2) 3,395 (85.9)
HIV-positive
g (% of all with
known status)
560 (18.4) 673 (19.8)
Self-rated health status
a,d (%)
—Most healthy 1,917 (59.3) 2,208 (61.4)
—Healthy 1,093 (33.8) 1,165 (32.4)
—Not healthy 167 (5.2) 159 (4.4)
—Least healthy 54 (1.7) 67 (1.9)
Manual worker (%) 2,792 (79.0) 3,033 (76.8)
Smoking
a,f (%)
—Never 2,288 (68.0) 2,615 (68.9)
—Currently 624 (18.5) 758 (20.0)
—Formerly 452 (13.4) 422 (11.1)
aAll employees identified through payroll records, including 135 employees in the off-site
and 201 employees in the on-site randomisation arms who did not consent to baseline
interview but did participate in the exit interview, and including 166 and 150 employees
in the off-site and on-site randomisation arms, respectively, who did not participate in
either the baseline or the exit interview but for whom basic demographic data on sex,
age, and job type were obtained from payroll records, where possible.
bNot available for 29 and 29 employees in off-site and on-site arms, respectively.
cNot available for 157 and 105 employees in off-site and on-site arms, respectively.
dNot available for the 301 and 351 employees who did not participate in the baseline
interview in off-site and on-site arms, respectively.
eIncludes divorced, separated, remarried, and widowed.
fNot available for the 166 and 150 employees in the off-site and on-site randomisation
arms, respectively, who did not participate in either the baseline or the exit interviews.
Smoking data missing for seven participants because of coding errors.
gFrom baseline and/or exit anonymized HIV tests. The denominator used for HIV
prevalence is employees of known HIV status (3,045 and 3,395 employees in off-site and
on-site arms, respectively).
SD, standard deviation.
DOI: 10.1371/journal.pmed.0030238.t001
Figure 2. Uptake of VCT or Vouchers (Percentage) by Site and Allocated
VCT Strategy
Each point represents uptake at one business. The horizontal bars
denote the mean site uptake within each category. aRR, risk ratio
adjusted for age, sex, marital status, education, household contact with
TB patients, self-rated health, and randomisation strata (see Table 2).
DOI: 10.1371/journal.pmed.0030238.g002
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Cluster-Randomised Trial of VCT Uptakeone another to be tested, were the less prominent peaks in
voucher uptake corresponding to periodic multiple requests
for vouchers from a single site (Figure 3).
Multiple VCT Uptake
Individual employees were not limited to a single VCT
episode, but could access services repeatedly for the 2-y study
period, with the only constraint being a minimum time
interval of 3 mo between VCT episodes. As part of post-test
counselling, HIV-negative individuals were routinely encour-
aged to attend for repeat testing at 3 mo to exclude the
‘‘window period’’ of early HIV infection without detectable
antibodies. However, apart from 388 participants in a sub-
study investigating routine repeat testing at 3 mo [19], repeat
episodes of VCT were uncommon, with only 9.6% of VCT
clients in the on-site testing arm and 5.1% of clients in the
off-site testing arm making repeat visits.
Factors Associated with Accepting On-Site VCT or
Vouchers for Off-Site VCT
Multivariate analysis of uptake of on-site VCT showed that
the following factors were signiﬁcantly associated with
accepting VCT: age below 25 y (adjusted odds ratio [OR]
1.8; 95% CI 1.3 to 2.4) or 45 y or older (OR 1.7; 95% CI 1.1 to
2.8), being single (OR 1.3; 95% CI 1.1 to 1.5), having had past
household exposure to TB (OR 1.2; 95% CI 1.0 to 1.4), having
a manual job (OR 1.7; 95% CI 1.3 to 2.1), and poorer self-
rated health (OR 1.4 per category below most healthy; 95% CI
1.2 to 1.7) (Table 3). Although not signiﬁcant in the univariate
analysis, HIV status was signiﬁcant in the multivariate
analysis, with HIV-positive employees being less likely to test
than their HIV-negative colleagues (OR 0.8; 95% CI 0.6 to
1.0).
Table 3 also shows the multivariate analysis of voucher
uptake in businesses allocated to off-site testing. Age below 25
y (OR 2.2; 95% CI 1.2 to 4.0), being single (OR 1.4; 95% CI 1.2
to 1.8), and having a manual job (OR 1.8; 95% CI 1.3 to 2.4)
were signiﬁcantly associated with accepting vouchers, while
voucher uptake among those aged 45 y or older was
signiﬁcantly less likely (OR 0.6; 95% CI 0.4 to 0.9). As at
businesses allocated rapid testing, HIV status was signiﬁcant
only in multivariate analysis, but in this case HIV-positive
employees were more likely to take vouchers than HIV-
negative employees (OR 1.3; 95% CI 1.1 to 1.6).
Discussion
The results of this study demonstrate the high potential of
rapid HIV testing and counselling at the workplace when this
is linked to basic HIV care (not including antiretroviral
therapy). Uptake of on-site rapid testing was signiﬁcantly and
substantially higher than that achieved through standard-of-
care provision of free vouchers for off-site VCT linked to the
same HIV care package (mean uptake of VCT by site 51.1%
and 4.3%, respectively). The time course of uptake at our
study sites (Figure 3) suggests that periodic outreach VCT
may be almost as effective as providing a continuous service.
We have separately reported the high reproducibility of on-
site HIV test results [19].
HIV testing and counselling is the gateway to HIV care, and
Table 2. Uptake of Vouchers and Off-Site VCT versus Uptake of On-Site VCT
Comparison Variable Off-Site (Mean) On-Site (Mean) Rank Sum (p-Value) Risk Ratio (95% CI)
Vouchers versus on-site VCT Number accepting/number of employees 586/3,532 1,957/3,950
Crude mean uptake 16.6% 49.5%
Unadjusted mean of uptake by site 19.2% 51.1% ,0.001 2.7 (1.8 to 3.9)
Observed/expected, adjusted for strata
a 0.564 1.503 ,0.001 2.7 (1.8 to 3.9)
Observed/expected, fully adjusted
b 0.534 1.506 ,0.001 2.8 (1.8 to 3.8)
Off-site VCT
c versus on-site VCT Number accepting/number of employees 125/3,532 1,957/3,950
Crude mean uptake 3.5% 49.5%
Unadjusted mean of uptake by site 4.3% 51.1% ,0.001 11.7 (7.9 to 17.4)
Observed/expected, adjusted for strata
a 0.154 1.840 ,0.001 11.9 (8.0 to 17.1)
Observed/expected, fully adjusted
b 0.146 1.830 ,0.001 12.5 (8.2 to 16.8)
aRatio of observed to expected proportions, adjusted for stratified randomisation.
bRatio of observed to expected proportions, adjusted for age, sex, marital status, education, household contact with TB patients, self-rated health, and strata.
cDefined as having both taken a voucher and reported attending an off-site VCT centre by the third reminder (see Methods).
DOI: 10.1371/journal.pmed.003023.t002
Figure 3. Timing of Uptake among Employees Who Accepted VCT or
Vouchers
Broken line denotes on-site VCT uptake; solid line denotes off-site
voucher uptake.
DOI: 10.1371/journal.pmed.0030238.g003
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Cluster-Randomised Trial of VCT Uptakemay also contribute to HIV prevention by reducing high-risk
sexual behaviour among individuals who know themselves to
be HIV-positive [2,20–22]. VCT has been identiﬁed as one of
the most cost-effective HIV/AIDS interventions in Africa [23].
Despite the high potential beneﬁt, there is limited under-
standing of factors that determine acceptability and uptake,
particularly for client-initiated testing outside of health-care
settings.
Evidence of high readiness to test but limited means and
motivation is available from other settings in Africa. Direct
offer of HIV testing in a convenient location usually leads to
high uptake in both health-care settings [7,10,24,25] and
community settings [6,12,13,26]. Acceptance of provider-
initiated testing can exceed 90% for antenatal clinic attend-
ees and patients presenting with opportunistic infections
[7,10,27], but with rates of return of only 45%–75% when a
repeat visit is required [4,27,28]. However, only a minority of
African adults will make unsolicited visits to free-standing or
clinic-based VCT centres [29]. Major disincentives include
fear of being seen, fear of breach of conﬁdentiality, inability
to cope or adverse life events if found to be positive, and a
sense of futility if testing is not linked to HIV care [13,30,31].
Accessibility and cost are also important [13,30,31]. Making
counselling and receipt of results available through home
visits increased uptake of community-based VCT from 10%–
12% to 37%–87% in four different African studies
[6,13,26,32]. Thus, the consistent ﬁnding is that relatively
minor differences in accessibility translate into major differ-
ences in acceptability of VCT in Africa. Similar observations
have been made in the United Kingdom and United States
[5,8].
Limitations of the current study are that the VCT
intervention was combined with basic HIV care, so the
acceptability of workplace VCT not linked to follow-up care
is uncertain. Serious adverse reactions to testing HIV-
positive, which we did not observe, could be more problem-
atic when ongoing counselling is not provided. These factors
may become less critical as public sector HIV care is scaled up
in Africa. Businesses were identiﬁed through an organisation
providing HIV prevention, and so there may be a selection
bias towards those that are unusually receptive to addressing
HIV issues. Operational studies of VCT uptake in the wider
business community, with and without linked HIV care
provision, are needed before our results can be more broadly
generalised.
Individual factors associated with accepting VCT and
vouchers were younger age, being single, manual work,
suboptimal health, HIV status, and previous household
contact with TB. The last may indicate greater readiness to
test among individuals from HIV-affected households, as TB
is strongly HIV-related in Harare [33]. Older employees were
less likely to take vouchers but more likely to accept rapid
VCT at the workplace than the reference age group of 30- to
34-y-olds, indicating that accessibility may be particularly
important for this age group. In multivariate analysis that
included self-rated health status, being HIV-positive signiﬁ-
cantly reduced the likelihood of accepting rapid VCT at the
workplace but signiﬁcantly increased the likelihood of
accepting a voucher. Unadjusted HIV prevalence among
clients accepting rapid VCT at the workplace was not
signiﬁcantly different from that of more comprehensive
Table 3. Univariate and Multivariate Adjusted OR (95% CI) of Factors Associated with VCT/Voucher Uptake
Characteristic Category Off-Site Voucher On-Site VCT
Univariate OR
a Multivariate OR
a Univariate OR
a Multivariate OR
a
Age group (years) 24 or younger 2.4 (1.4 to 4.2) 2.2 (1.2 to 4.0) 2.0 (1.5 to 2.7) 1.8 (1.3 to 2.4)
25 to 29 1.3 (0.9 to 2.0) 1.4 (1.0 to 2.1) 1.3 (1.1 to 1.5) 1.2 (1.0 to 1.5)
30 to 34 1 1 1 1
35 to 44 1.1 (0.8 to 1.6) 1.1 (0.7 to 1.5) 1.5 (1.0 to 2.2) 1.5 (1.0 to 2.4)
45 or older 0.6 (0.4 to 1.0) 0.6 (0.4 to 0.9) 1.7 (1.2 to 2.4) 1.7 (1.0 to 2.8)
Gender Female 1 1 1 1
Male 1.0 (0.6 to 1.8) 1.1 (0.6 to 2.2) 0.9 (0.7 to 1.3) 0.8 (0.6 to 1.1)
Marital status Married/cohabiting 1 1 1 1
Single 2.2 (1.5 to 3.1) 1.4 (1.2 to 1.8) 1.4 (1.2 to 1.8) 1.3 (1.1 to 1.5)
Previously married 1.7 (1.2 to 2.5) 1.6 (0.9 to 2.7) 1.4 (0.9 to 2.2) 1.5 (1.0 to 2.2)
Education None/primary 1 — 1 —
Secondary 1.8 (1.2 to 2.8) — 0.8 (0.6 to 1.0) —
Higher 1.0 (0.4 to 2.1) — 0.6 (0.4 to 0.8) —
Religion Christian 1 — 1 —
None/other 1.1 (0.8 to 1.4) — 1.0 (0.9 to 1.2) —
Job type Administrative 1 1 1 1
Manual 2.1 (1.6 to 2.7) 1.8 (1.3 to 2.4) 1.7 (1.3 to 2.2) 1.7 (1.3 to 2.1)
Past household contact with TB No 1 1 1 1
Yes 1.3 (0.9 to 1.8) 1.2 (0.9 to 1.6) 1.3 (1.2 to 1.6) 1.2 (1.0 to 1.4)
HIV status Negative 1 1 1 1
Positive 1.3 (0.9 to 1.8) 1.3 (1.1 to 1.6) 0.9 (0.7 to 1.1) 0.8 (0.6 to 1.0)
Self-reported health status Most healthy 1 1 1 1
Per category below most healthy
b 1.2 (0.9 to 1.7) 1.3 (0.9 to 1.7) 1.4 (1.2 to 1.7) 1.4 (1.2 to 1.7)
aORs calculated by logistic regression using robust standard errors. All variables included in the multivariate analysis are shown. Level of education was not significant on multivariate
adjustment and so was not included in the final model.
bOR per category below the ‘‘most healthy’’ reference group, with variable analysed as an ordered categorical.
DOI: 10.1371/journal.pmed.0030238.t003
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Cluster-Randomised Trial of VCT Uptakeanonymised HIV testing, however, and the on-site strategy
was still the most effective among HIV-infected persons.
A study of population-based counselling in Uganda also
reported that HIV prevalence in VCT clients was very similar
to that of anonymised HIV testing, but with over-representa-
tion of individuals with symptomatic HIV disease and under-
representation of individuals with asymptomatic HIV infec-
tion [11,12]. Taken with the current results, this suggests that
high-impact VCT campaigns may provide useful population
HIV prevalence estimates, but with over-estimation of the
prevalence of symptomatic HIV and AIDS.
Policies towards the provision of diagnostic HIV testing
services in Africa have undergone a major transformation in
the last few years, from stressing the potential harm to
stressing the need to achieve greater accessibility [34,35].
Rapid HIV testing has minimal infrastructure requirements,
can be performed accurately by non-laboratory personnel
after brief training, and has expanded the potential scope of
community-based VCT [35]. Further research is needed to
conﬁrm the high acceptability and to identify barriers to
accepting rapid testing at the workplace. A key question will
be whether VCT at the workplace, which essentially excludes
couple counselling for most clients, is as effective for HIV
prevention as other modes of delivering VCT. High-impact
strategies aiming to ‘‘normalise’’ knowledge of HIV serostatus
are under trial at present. Our results suggest that high
accessibility will be a key requirement, and that including the
workplace may contribute towards the realisation of this goal.
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Editors’ Summary
Background. Since the first case of AIDS (acquired immunodeficiency
syndrome) was reported 25 years ago, AIDS has become a major
worldwide epidemic, with 3 million people dying from it in 2005. AIDS is
caused by the human immunodeficiency virus (HIV), which is usually
spread through unprotected sex with an infected partner. HIV damages
the immune system, leaving infected individuals unable to fight off other
viruses and bacteria. HIV infections can be treated with drugs know as
‘‘antiretrovirals,’’ and in an effort to deal with the global epidemic, world
leaders have committed themselves to providing universal access to
these drugs for everyone who needs them by 2010. Unfortunately,
although access to antiretrovirals is rapidly increasing, so is the number
of people infected with HIV. Last year, there were about 5 million new
HIV infections, suggesting that more emphasis on prevention will be
needed to halt or reverse the spread of HIV and AIDS. An important part
of prevention is testing for HIV infection, but globally only 10% of people
who need testing can access it. And even where such services are
available, few people use them because of the stigma attached to HIV
infection and fear of discrimination.
Why Was This Study Done? There is limited understanding about the
factors that determine whether an individual will decide to have an HIV
test. Yet, to reduce HIV spread, as many people at risk of infection must
be tested as possible. Previous studies on VCT—a combination of
voluntary testing and counseling about the implications of HIV infection
and how to avoid transmitting the virus—have indicated that the
convenience of getting the test, whether the test is directly offered, and
the attitude of staff supplying it are all very important. In this study, the
researchers asked whether providing VCT in the workplace could
improve the ‘‘uptake’’ of HIV testing in Africa, where the HIV/AIDS
epidemic is most widespread.
What Did the Researchers Do and Find? The researchers identified
businesses with occupational health clinics in Zimbabwe, a country
where 25% of adults carry HIV, and divided them into two ‘‘intervention’’
groups. Employees at half the businesses were offered ‘‘on-site VCT’’—
pre-test counseling followed by same-day on-site rapid testing, results,
and post-test counseling. Employees at the other businesses had the
same pre-test counseling but were offered a voucher for an HIV test at
an off-site testing center and a later appointment to discuss the results—
so-called off-site VCT. Everyone had the same access to limited HIV care
should they need it. Although half of the employees at the on-site VCT
businesses took up the option of HIV testing, only a fifth of employees at
the off-site VCT businesses accepted vouchers for testing, and only one
in five of these people actually used their voucher. This means that on-
site VCT resulted in about 12 times as many HIV tests as off-site VCT. In
both interventions, most of the people who accepted testing did so soon
after entering the study and very few people were tested more than
once. Finally, people 25 years old or younger, manual workers, and single
people were most likely to accept testing in both interventions.
What Do These Findings Mean? These results suggest that on-site VCT
in the workplace might be one way to improve uptake of HIV testing in
Africa from its current low level and that providing VCT intermittently
might be as effective as continuous provision. Importantly, say the
researchers, the results of their study show that a relatively minor change
in accessibility to testing can translate into a major difference in test
uptake. This may hold true in non-occupational settings. However, these
observations need to be repeated in more businesses and other settings,
including those where there is no linked HIV care, before they can be
generalized. Also, this study reports on the acceptability of this approach
to providing VCT, but not on its impact on HIV prevention. As such the
results do not indicate whether workplace VCT prevents HIV spread as
effectively as other ways of delivering VCT. This will require research
investigating how HIV incidence among HIV-negative employees and the
partners of HIV-positive employees are affected by different VCT
strategies.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030238.
  United States National Institute of Allergy and Infectious Diseases
factsheet on HIV infection and AIDS
  United States Department of Health and Human Services information
on HIV/AIDS treatment, prevention, and research
  US Centers for Disease Control and Prevention information on HIV/
AIDS
  UNAIDS (Joint United Nations Programme on HIV/AIDS) information on
political issues related to the HIV/AIDS epidemic and the 2004 UNAIDS/
World Health Organization policy statement on HIV testing
  Aidsmap: information on HIV and AIDS provided by the charity NAM,
which includes the latest scientific and political news
  MedlinePlus encyclopedia entry on HIV/AIDS
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